(A) Pie charts showing the percentage of MATR3 targets in CharmeKO downregulated, invariant, or upregulated differentially expressed genes (DEGs). Significance of enrichment or depletion was assessed with two-sided Fisher’s exact test, shown below. (B) MATR3 targets (%) in the GO categories enriching CharmeKO downregulated DEGs (Down-DEGs) (see also Figure 2A). (C) Profile heatmaps of differential MATR3 CLIP-seq peaks (CharmeWT vs. CharmeKO). Normalized mean read counts of both IP samples are shown only for significant (false discovery rate [FDR] < 0.05) ‘Gain’ and ‘Loss’ peaks. (D) Upper panel: histogram showing the distribution (%) of ‘Gain’ and ‘Loss’ MATR3 peaks in pCharme DEGs. Significance of enrichment was assessed with two-sided Fisher’s exact test. Lower panel: distribution of the subset (13 out of 20) of Down-DEGs with Loss peaks in the first three GO categories identified for downregulated genes (see also Figure 2A). (E) Left panel: schematic representation of primary cells extraction from CharmeWT hearts. Once isolated, cells were plated and transfected with the specific siRNA (si-Matr3) or control siRNA (si-SCR). See ‘Materials and methods’ for details. Right panel: RT-qPCR quantification of Matr3, Cacna1c, Notch3, Myo18b, and Rbm20 RNA levels in primary cardiac cells treated with si-SCR or si-Matr3. Data were normalized to Gapdh mRNA and represent mean ± SEM of (n=4) independent biological experiments. Data information: *p<0.05; **p<0.01; ***p<0.001, unpaired Student’s t-test.